Clinical Report: Over 40,000 Hematopoietic Stem Cell Transplants Performed in Europe in 2014
Overview
In 2014, Europe reported a record 40,829 hematopoietic stem cell transplants (HSCT) in 36,469 patients, marking a significant increase in transplant activity. Allogeneic transplants accounted for 42% and autologous for 58%, with a notable rise in both types compared to previous years.
Background
Hematopoietic stem cell transplantation (HSCT) is a critical treatment for various hematopoietic, immune, and metabolic disorders. The European Society of Blood and Marrow Transplantation (EBMT) annually surveys HSCT activity across Europe and affiliated countries to monitor trends and technological advances. The 2014 survey included data from 656 centers in 49 countries, capturing detailed information on transplant indications, donor types, and stem cell sources. This comprehensive data collection allows for evaluation of changes in HSCT practices over time.
Data Highlights
Parameter
2014 Data
Total transplants
40,829
Patients transplanted (first transplant)
36,469
Allogeneic HSCT
16,946 (42%)
Autologous HSCT
23,883 (58%)
Increase from 2013
4.1% total (4.5% allogeneic, 3.8% autologous)
Second or subsequent transplants
4,360 (1,181 allogeneic, 3,179 autologous)
Increase over 5 years (since 2010)
22%
Increase over 15 years (since 2000)
80%
Patients under 18 years
4,400 (3,279 allogeneic, 1,121 autologous)
Dedicated pediatric centers performing HSCT
3,117 patients (71% of pediatric transplants)
Key Findings
In 2014, 656 centers from 49 countries reported HSCT data with a 97% response rate.
Allogeneic HSCT represented 42% and autologous HSCT 58% of total transplants performed.
The total number of HSCT increased by 4.1% compared to 2013, continuing a long-term upward trend.
There was a 22% increase in total transplants over the past 5 years and an 80% increase over 15 years.
Approximately 12% of transplants were performed in pediatric patients, predominantly in dedicated pediatric centers.
Donor types included HLA identical siblings, matched unrelated donors, and haploidentical mismatched family donors, with detailed categorization in the survey.
Clinical Implications
The continued increase in HSCT activity underscores the expanding role of transplantation in treating hematologic and immune disorders. The data highlight the importance of diverse donor sources, including haploidentical donors, to broaden patient access. Pediatric transplantation remains a significant component, necessitating specialized centers. Clinicians should be aware of evolving trends to optimize donor selection and transplant strategies.
Conclusion
The 2014 EBMT survey demonstrates a sustained growth in hematopoietic stem cell transplantation across Europe and affiliated countries, reflecting advances in transplant technology and expanding indications. Ongoing monitoring is essential to guide clinical practice and resource allocation.
References
EBMT Activity Survey 2014 -- Annual Hematopoietic Stem Cell Transplant Procedures in Europe Exceed 40,000
by J R Passweg, H Baldomero, P Bader, C Bonini, S Cesaro, P Dreger, R F Duarte, C Dufour, J Kuball, D Farge-Bancel, A Gennery, N Kröger, F Lanza, A Nagler, A Sureda, M Mohty
